BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hao C, Zhu PX, Yang X, Han ZP, Jiang JH, Zong C, Zhang XG, Liu WT, Zhao QD, Fan TT. Overexpression of SIRT1 promotes metastasis through epithelial-mesenchymal transition in hepatocellular carcinoma. BMC Cancer. 2014;14:978. [PMID: 25522783 DOI: 10.1186/1471-2407-14-978] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 9.1] [Reference Citation Analysis]
Number Citing Articles
1 Wu S, Jiang J, Liu J, Wang X, Gan Y, Tang Y. Meta-analysis of SIRT1 expression as a prognostic marker for overall survival in gastrointestinal cancer. Oncotarget 2017;8:62589-99. [PMID: 28977971 DOI: 10.18632/oncotarget.19880] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
2 Dalamaga M, Christodoulatos GS. Visfatin, Obesity, and Cancer. In: Reizes O, Berger NA, editors. Adipocytokines, Energy Balance, and Cancer. Cham: Springer International Publishing; 2017. pp. 109-36. [DOI: 10.1007/978-3-319-41677-9_6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
3 Mvunta DH, Miyamoto T, Asaka R, Yamada Y, Ando H, Higuchi S, Ida K, Kashima H, Shiozawa T. SIRT1 Regulates the Chemoresistance and Invasiveness of Ovarian Carcinoma Cells. Transl Oncol 2017;10:621-31. [PMID: 28667895 DOI: 10.1016/j.tranon.2017.05.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
4 Wu Y, Meng X, Huang C, Li J. Emerging role of silent information regulator 1 (SIRT1) in hepatocellular carcinoma: a potential therapeutic target. Tumor Biol 2015;36:4063-74. [DOI: 10.1007/s13277-015-3488-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
5 Carafa V, Altucci L, Nebbioso A. Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype. Front Pharmacol 2019;10:38. [PMID: 30761005 DOI: 10.3389/fphar.2019.00038] [Cited by in Crossref: 54] [Cited by in F6Publishing: 38] [Article Influence: 27.0] [Reference Citation Analysis]
6 Farcas M, Gavrea AA, Gulei D, Ionescu C, Irimie A, Catana CS, Berindan-Neagoe I. SIRT1 in the Development and Treatment of Hepatocellular Carcinoma. Front Nutr 2019;6:148. [PMID: 31608282 DOI: 10.3389/fnut.2019.00148] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
7 Zhao J, Gray SG, Greene CM, Lawless MW. Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer. Expert Review of Gastroenterology & Hepatology 2019;13:247-56. [DOI: 10.1080/17474124.2019.1568870] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
8 Qiu L, Wang T, Xu X, Wu Y, Tang Q, Chen K. Long Non-Coding RNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: Regulation, Functions, and Underlying Mechanisms. Int J Mol Sci 2017;18:E2505. [PMID: 29168767 DOI: 10.3390/ijms18122505] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
9 Qian YY, Li K, Liu QY, Liu ZS. Long non-coding RNA PTENP1 interacts with miR-193a-3p to suppress cell migration and invasion through the PTEN pathway in hepatocellular carcinoma. Oncotarget 2017;8:107859-69. [PMID: 29296207 DOI: 10.18632/oncotarget.22305] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
10 Neuman MG, Malnick S, Maor Y, Nanau RM, Melzer E, Ferenci P, Seitz HK, Mueller S, Mell H, Samuel D, Cohen LB, Kharbanda KK, Osna NA, Ganesan M, Thompson KJ, Mckillop IH, Bautista A, Bataller R, French SW. Alcoholic liver disease: Clinical and translational research. Experimental and Molecular Pathology 2015;99:596-610. [DOI: 10.1016/j.yexmp.2015.09.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
11 Hu L, Ye H, Huang G, Luo F, Liu Y, Liu Y, Yang X, Shen J, Liu Q, Zhang J. Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21. Tumour Biol. 2016;37:2691-2702. [PMID: 26404135 DOI: 10.1007/s13277-015-4111-x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 95] [Article Influence: 15.5] [Reference Citation Analysis]
12 Jiang H, Zhang X, Tao Y, Shan L, Jiang Q, Yu Y, Cai F, Ma L. Prognostic and clinicopathologic significance of SIRT1 expression in hepatocellular carcinoma. Oncotarget 2017;8:52357-65. [PMID: 28881735 DOI: 10.18632/oncotarget.14096] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
13 Wu Q, Wang Y, Qian M, Qiao Y, Zou S, Chen C, Zhang X, Chen Y, Zhao Y, Zhu G, Chen Y, Sun F, Wang J, Pan Q. Sirt1 suppresses Wnt/βCatenin signaling in liver cancer cells by targeting βCatenin in a PKAα-dependent manner. Cellular Signalling 2017;37:62-73. [DOI: 10.1016/j.cellsig.2017.06.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
14 Jiang G, Wen L, Zheng H, Jian Z, Deng W. miR-204-5p targeting SIRT1 regulates hepatocellular carcinoma progression: miR-204-5p inhibits hepatocellular carcinoma progression. Cell Biochem Funct 2016;34:505-10. [DOI: 10.1002/cbf.3223] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
15 Islam S, Abiko Y, Uehara O, Chiba I. Sirtuin 1 and oral cancer. Oncol Lett 2019;17:729-38. [PMID: 30655824 DOI: 10.3892/ol.2018.9722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
16 Tian Z, Jiang H, Liu Y, Huang Y, Xiong X, Wu H, Dai X. MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1. Exp Cell Res. 2016;343:135-147. [PMID: 27090017 DOI: 10.1016/j.yexcr.2016.03.027] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
17 Palmirotta R, Cives M, Della-Morte D, Capuani B, Lauro D, Guadagni F, Silvestris F. Sirtuins and Cancer: Role in the Epithelial-Mesenchymal Transition. Oxid Med Cell Longev 2016;2016:3031459. [PMID: 27379175 DOI: 10.1155/2016/3031459] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 7.6] [Reference Citation Analysis]
18 Choupani J, Mansoori Derakhshan S, Bayat S, Alivand MR, Shekari Khaniani M. Narrower insight to SIRT1 role in cancer: A potential therapeutic target to control epithelial-mesenchymal transition in cancer cells. J Cell Physiol 2018;233:4443-57. [PMID: 29194618 DOI: 10.1002/jcp.26302] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
19 Jiang J, Ye F, Yang X, Zong C, Gao L, Yang Y, Zhao Q, Han Z, Wei L. Peri-tumor associated fibroblasts promote intrahepatic metastasis of hepatocellular carcinoma by recruiting cancer stem cells. Cancer Lett 2017;404:19-28. [PMID: 28716525 DOI: 10.1016/j.canlet.2017.07.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
20 Novak Kujundžić R, Prpić M, Đaković N, Dabelić N, Tomljanović M, Mojzeš A, Fröbe A, Trošelj KG. Nicotinamide N-Methyltransferase in Acquisition of Stem Cell Properties and Therapy Resistance in Cancer. Int J Mol Sci 2021;22:5681. [PMID: 34073600 DOI: 10.3390/ijms22115681] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Zhang Y, Yang L, Wang S, Liu Z, Xiu M. MiR-29a suppresses cell proliferation by targeting SIRT1 in hepatocellular carcinoma. CBM 2018;22:151-9. [DOI: 10.3233/cbm-171120] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
22 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584-10597. [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 40] [Article Influence: 7.4] [Reference Citation Analysis]
23 Zhang Z, Chen X, Liu S. Role of Sirtuin-1 in Neonatal Hypoxic-Ischemic Encephalopathy and Its Underlying Mechanism. Med Sci Monit 2020;26:e924544. [PMID: 32826847 DOI: 10.12659/MSM.924544] [Reference Citation Analysis]
24 Díaz L, Díaz-Muñoz M, García-Gaytán AC, Méndez I. Mechanistic Effects of Calcitriol in Cancer Biology. Nutrients 2015;7:5020-50. [PMID: 26102214 DOI: 10.3390/nu7065020] [Cited by in Crossref: 53] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
25 Lou T, Huang Q, Su H, Zhao D, Li X. Targeting Sirtuin 1 signaling pathway by ginsenosides. J Ethnopharmacol 2021;268:113657. [PMID: 33276056 DOI: 10.1016/j.jep.2020.113657] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Wang C, Yang W, Dong F, Guo Y, Tan J, Ruan S, Huang T. The prognostic role of Sirt1 expression in solid malignancies: a meta-analysis. Oncotarget 2017;8:66343-51. [PMID: 29029516 DOI: 10.18632/oncotarget.18494] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
27 Zhao L, Cao J, Hu K, Wang P, Li G, He X, Tong T, Han L. RNA-binding protein RPS3 contributes to hepatocarcinogenesis by post-transcriptionally up-regulating SIRT1. Nucleic Acids Res 2019;47:2011-28. [PMID: 30517713 DOI: 10.1093/nar/gky1209] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
28 Jin MS, Hyun CL, Park IA, Kim JY, Chung YR, Im SA, Lee KH, Moon HG, Ryu HS. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer. Tumour Biol 2016;37:4743-53. [PMID: 26515337 DOI: 10.1007/s13277-015-4231-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
29 Farghali H, Kemelo MK, Canová NK. SIRT1 Modulators in Experimentally Induced Liver Injury. Oxid Med Cell Longev 2019;2019:8765954. [PMID: 31281594 DOI: 10.1155/2019/8765954] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
30 Dalamaga M, Christodoulatos GS, Mantzoros CS. The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: Diagnostic and therapeutic perspectives and challenges. Metabolism. 2018;82:72-87. [PMID: 29330025 DOI: 10.1016/j.metabol.2018.01.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
31 Molla MD, Dessie G, Akalu Y, Ayelign B. Hepatocellular Expression of SIRT1 and Its Effect on Hepatocellular Carcinoma Progression: A Future Therapeutic Perspective. Int J Hepatol 2020;2020:2374615. [PMID: 32607257 DOI: 10.1155/2020/2374615] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Chen Y, Wang T, Wang W, Hu J, Li R, He S, Yang J. Prognostic and clinicopathological significance of SIRT1 expression in NSCLC: a meta-analysis. Oncotarget 2017;8:62537-44. [PMID: 28977967 DOI: 10.18632/oncotarget.19244] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
33 Sun M, Du M, Zhang W, Xiong S, Gong X, Lei P, Zha J, Zhu H, Li H, Huang D, Gu X. Survival and Clinicopathological Significance of SIRT1 Expression in Cancers: A Meta-Analysis. Front Endocrinol (Lausanne) 2019;10:121. [PMID: 30930849 DOI: 10.3389/fendo.2019.00121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
34 Wang Y, Xu H, Fu W, Lu Z, Guo M, Wu X, Sun M, Liu Y, Yu X, Sui D. 20(S)-Protopanaxadiol Inhibits Angiotensin II-Induced Epithelial- Mesenchymal Transition by Downregulating SIRT1. Front Pharmacol 2019;10:475. [PMID: 31133857 DOI: 10.3389/fphar.2019.00475] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
35 Wang Q, Cheng ST, Chen J. HBx mediated Increase of SIRT1 Contributes to HBV-related Hepatocellular Carcinoma Tumorigenesis. Int J Med Sci 2020;17:1783-94. [PMID: 32714081 DOI: 10.7150/ijms.43491] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Ceballos MP, Decándido G, Quiroga AD, Comanzo CG, Livore VI, Lorenzetti F, Lambertucci F, Chazarreta-Cifre L, Banchio C, Alvarez ML, Mottino AD, Carrillo MC. Inhibition of sirtuins 1 and 2 impairs cell survival and migration and modulates the expression of P-glycoprotein and MRP3 in hepatocellular carcinoma cell lines. Toxicol Lett 2018;289:63-74. [PMID: 29545174 DOI: 10.1016/j.toxlet.2018.03.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
37 Luo X, Zhao X, Cheng C, Li N, Liu Y, Cao Y. The implications of signaling lipids in cancer metastasis. Exp Mol Med 2018;50:1-10. [PMID: 30242145 DOI: 10.1038/s12276-018-0150-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 14.0] [Reference Citation Analysis]
38 Roberti A, Fernández AF, Fraga MF. Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation. Mol Metab 2021;45:101165. [PMID: 33453420 DOI: 10.1016/j.molmet.2021.101165] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
39 Yuan T, Chen Z, Yan F, Qian M, Luo H, Ye S, Cao J, Ying M, Dai X, Gai R, Yang B, He Q, Zhu H. Deubiquitinating enzyme USP10 promotes hepatocellular carcinoma metastasis through deubiquitinating and stabilizing Smad4 protein. Mol Oncol 2020;14:197-210. [PMID: 31721429 DOI: 10.1002/1878-0261.12596] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
40 Tan YJ, Lee YT, Yeong KY, Petersen SH, Kono K, Tan SC, Oon CE. Anticancer activities of a benzimidazole compound through sirtuin inhibition in colorectal cancer. Future Medicinal Chemistry 2018;10:2039-57. [DOI: 10.4155/fmc-2018-0052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
41 Sun T, Jiao L, Wang Y, Yu Y, Ming L. SIRT1 induces epithelial-mesenchymal transition by promoting autophagic degradation of E-cadherin in melanoma cells. Cell Death Dis 2018;9:136. [PMID: 29374154 DOI: 10.1038/s41419-017-0167-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
42 Zhang N, Xie T, Xian M, Wang YJ, Li HY, Ying MD, Ye ZM. SIRT1 promotes metastasis of human osteosarcoma cells. Oncotarget 2016;7:79654-69. [PMID: 27793039 DOI: 10.18632/oncotarget.12916] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
43 Ceballos MP, Angel A, Delprato CB, Livore VI, Ferretti AC, Lucci A, Comanzo CG, Alvarez ML, Quiroga AD, Mottino AD, Carrillo MC. Sirtuin 1 and 2 inhibitors enhance the inhibitory effect of sorafenib in hepatocellular carcinoma cells. Eur J Pharmacol 2021;892:173736. [PMID: 33220273 DOI: 10.1016/j.ejphar.2020.173736] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
44 Huang Z, Zhang W, Gao C, Ji B, Chi X, Zheng W, Wang HL. Dysregulation of GTPase IMAP family members in hepatocellular cancer. Mol Med Rep 2016;14:4119-23. [PMID: 27667392 DOI: 10.3892/mmr.2016.5764] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
45 Chimento A, De Luca A, Nocito MC, Sculco S, Avena P, La Padula D, Zavaglia L, Sirianni R, Casaburi I, Pezzi V. SIRT1 is involved in adrenocortical cancer growth and motility. J Cell Mol Med 2021;25:3856-69. [PMID: 33650791 DOI: 10.1111/jcmm.16317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Zhang B, Shi D, Zhang X, Liang G, Liu W, Qiao S. FK866 inhibits the epithelial-mesenchymal transition of hepatocarcinoma MHCC97-H cells. Oncol Lett. 2018;16:7231-7238. [PMID: 30546461 DOI: 10.3892/ol.2018.9541] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
47 Lee J, You JH, Kim MS, Roh JL. Epigenetic reprogramming of epithelial-mesenchymal transition promotes ferroptosis of head and neck cancer. Redox Biol 2020;37:101697. [PMID: 32896720 DOI: 10.1016/j.redox.2020.101697] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
48 Garcia-Peterson LM, Li X. Trending topics of SIRT1 in tumorigenicity. Biochim Biophys Acta Gen Subj 2021;1865:129952. [PMID: 34147543 DOI: 10.1016/j.bbagen.2021.129952] [Reference Citation Analysis]
49 Yan T, Huang J, Nisar MF, Wan C, Huang W. The Beneficial Roles of SIRT1 in Drug-Induced Liver Injury. Oxid Med Cell Longev 2019;2019:8506195. [PMID: 31354914 DOI: 10.1155/2019/8506195] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
50 Wang X, Du G, Wu Y, Zhang Y, Guo F, Liu W, Wu R. Association between different levels of lipid metabolism‑related enzymes and fatty acid synthase in Wilms' tumor. Int J Oncol 2020;56:568-80. [PMID: 31894270 DOI: 10.3892/ijo.2019.4948] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Wang W, Im J, Kim S, Jang S, Han Y, Yang KM, Kim SJ, Dhanasekaran DN, Song YS. ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer. Antioxidants (Basel) 2020;9:E1137. [PMID: 33207824 DOI: 10.3390/antiox9111137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
52 Kumar P, Sharad S, Petrovics G, Mohamed A, Dobi A, Sreenath TL, Srivastava S, Biswas R. Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1. Oncotarget 2016;7:22791-806. [PMID: 26988912 DOI: 10.18632/oncotarget.8061] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
53 Cseh AM, Fábián Z, Sümegi B, Scorrano L. Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors. Oncotarget 2017;8:50221-39. [PMID: 28430591 DOI: 10.18632/oncotarget.16859] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
54 Skrypek N, Bruneel K, Vandewalle C, De Smedt E, Soen B, Loret N, Taminau J, Goossens S, Vandamme N, Berx G. ZEB2 stably represses RAB25 expression through epigenetic regulation by SIRT1 and DNMTs during epithelial-to-mesenchymal transition. Epigenetics Chromatin 2018;11:70. [PMID: 30445998 DOI: 10.1186/s13072-018-0239-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
55 Zhou J, Zhou W, Kong F, Xiao X, Kuang H, Zhu Y. microRNA-34a overexpression inhibits cell migration and invasion via regulating SIRT1 in hepatocellular carcinoma. Oncol Lett 2017;14:6950-4. [PMID: 29344126 DOI: 10.3892/ol.2017.7090] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
56 Cheng F, Su L, Yao C, Liu L, Shen J, Liu C, Chen X, Luo Y, Jiang L, Shan J, Chen J, Zhu W, Shao J, Qian C. SIRT1 promotes epithelial-mesenchymal transition and metastasis in colorectal cancer by regulating Fra-1 expression. Cancer Lett. 2016;375:274-283. [PMID: 26975631 DOI: 10.1016/j.canlet.2016.03.010] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
57 Feng H, Wang J, Xu J, Xie C, Gao F, Li Z. The expression of SIRT1 regulates the metastaticplasticity of chondrosarcoma cells by inducing epithelial-mesenchymal transition. Sci Rep 2017;7:41203. [PMID: 28112277 DOI: 10.1038/srep41203] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]